Is There a Lyme Vaccine for Humans? What Happened to LYMErix
There is currently no Lyme vaccine for humans.
The LYMErix vaccine was withdrawn in 2002.
New vaccines are being developed—but questions remain.
There is currently no approved Lyme disease vaccine for humans. A previous vaccine, LYMErix, was withdrawn from the market in 2002.
Short answer: No—there is currently no Lyme vaccine available for people.
The withdrawal followed declining demand and concerns about possible autoimmune side effects, though a clear causal link was never definitively established.
Since then, researchers have continued efforts to develop a new vaccine—but challenges remain.
What Happened to the LYMErix Vaccine?
LYMErix was introduced in the late 1990s and was approximately 80% effective at preventing an erythema migrans rash. However, its effectiveness dropped to about 50% when broader definitions of Lyme disease were used.
The vaccine required three doses over two tick seasons, with additional boosters likely needed.
The biggest concern was the possibility of an autoimmune reaction in some patients. This concern—combined with limited public acceptance—contributed to its withdrawal.
At the time, even experts expressed hesitation. At one conference, only a small number of physicians indicated they would personally take the vaccine.
Why Is There No Lyme Vaccine for Humans?
Several factors contributed to the absence of a current Lyme vaccine, including safety concerns, limited demand for the original vaccine, and the complexity of developing protection against multiple strains of Borrelia.
Public confidence also plays a major role—questions surrounding LYMErix continue to influence acceptance of future vaccines.
Why Developing a Lyme Vaccine Is Challenging
Lyme disease is caused by multiple strains of Borrelia, which vary geographically and biologically.
This variability makes it difficult to develop a vaccine that provides broad protection.
In addition, concerns about safety, public acceptance, and long-term effectiveness continue to complicate development efforts.
Are New Lyme Disease Vaccines Being Developed?
Yes. Several new Lyme disease vaccines are currently under development.
One candidate from a European company targets multiple strains of Borrelia and has received fast-track designation from the FDA.
Other approaches are exploring different targets, including outer surface proteins such as OspC, which vary between strains.
Newer vaccines are being designed to avoid components that were previously linked to safety concerns.
What Patients Are Asking Today
Many clinicians and patients remain cautious about future Lyme vaccines until the history of LYMErix is fully understood.
Concerns about safety, transparency, and effectiveness continue to influence acceptance.
This is particularly important given that current vaccine approaches do not address co-infections transmitted by ticks.
Could the Future of Prevention Look Different?
Some researchers are exploring alternatives to traditional vaccines.
One promising idea is targeting the tick itself—specifically proteins in tick saliva or the mid-gut—to prevent transmission before infection occurs.
This approach could potentially protect against multiple tick-borne diseases, not just Lyme disease.
Until a vaccine becomes available, prevention strategies such as tick bite prevention remain essential.
Clinical Perspective
Lyme disease vaccine development remains an evolving area.
While new vaccines may become available, questions about safety, effectiveness, and acceptance will play a critical role in their success.
Until then, prevention and early recognition remain essential.
Frequently Asked Questions
Is there a Lyme vaccine for humans?
No. There is currently no approved Lyme vaccine for humans.
Why was LYMErix withdrawn?
It was withdrawn due to declining demand and concerns about possible autoimmune reactions.
Are new vaccines coming?
Yes. Several vaccines are in development, but none are currently approved.
Will a vaccine prevent all tick-borne diseases?
No. Current vaccine approaches focus on Lyme disease and do not protect against co-infections.
References
- Shaffer L. Lyme disease vaccines face familiar challenges. Proc Natl Acad Sci U S A. 2019.
Dr. Daniel Cameron, MD, MPH
Lyme disease clinician with over 30 years of experience and past president of ILADS.
Symptoms • Testing • Coinfections • Recovery • Pediatric • Prevention
